...
首页> 外文期刊>Infectious Agents and Cancer >Bacteria under SOS evolve anticancer phenotypes
【24h】

Bacteria under SOS evolve anticancer phenotypes

机译:SOS下的细菌进化出抗癌表型

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The anticancer drugs, such as DNA replication inhibitors, stimulate bacterial adhesion and induce the bacterial SOS response. As a variety of bacterial mutants can be generated during SOS, novel phenotypes are likely to be selected under the drug pressure. Presentation of the hypothesis Bacteria growing with cancer cells in the presence of the replication inhibitors undergo the SOS response and evolve advantageous phenotypes for the bacteria to invade the cancer cells in order to evade the drug attack. This hypothesis predicts that bacteria produce the proteins that mediate bacterial capture and invasion of cancer cells--the advantageous phenotypes. Generation of the phenotypes may be facilitated during the SOS response induced by anticancer drugs. Testing the hypothesis Experimental design: 1) Examine attachment and invasion of bacterium Pseudomonas aeruginosa and the SOS mutant control to cancer cells in the presence of the anticancer drugs that inhibit DNA replication enzymes and trigger the SOS response. 2) Reveal the bacterial proteins that exhibit changes in expression. 3) Identify the genes encoding cancer adhesion and invasion. 4) Construct the mutants for the genes, clone and express these genes. 5) Examine the bacterial capture and invasion of cancer cells in contrast to non-cancer control. Expected results: 1) The bacterial proteins will be differentially induced during bacteria-cancer interaction under the SOS response to the anticancer drugs. 2) Knocking out the bacterial cancer-adhesion-invasion genes will disrupt the adhesion-invasion phenotypes of the bacteria. 3) Expressing these genes will direct the bacterial capture and invasion of cancer cells. Implications of the hypothesis Bacteria can evolve anticancer phenotypes targeting metastatic cells. If this hypothesis is true, the outcomes will contribute to development of a novel bacterial anti-metastasis regimen.
机译:背景技术抗癌药,例如DNA复制抑制剂,可刺激细菌黏附并诱导细菌SOS反应。由于在SOS期间可以产生多种细菌突变体,因此很可能在药物压力下选择新的表型。假说的提出在复制抑制剂的存在下,与癌细胞一起生长的细菌会经历SOS反应,并进化出有利的表型,使细菌入侵癌细胞,从而逃避药物攻击。该假设预测细菌会产生介导细菌捕获和侵袭癌细胞的蛋白质-有利的表型。在抗癌药诱导的SOS反应过程中可以促进表型的产生。测试假设的实验设计:1)在存在抑制DNA复制酶并触发SOS反应的抗癌药物的情况下,检查铜绿假单胞菌细菌的附着和侵袭以及SOS突变体对癌细胞的控制。 2)揭示表现出表达变化的细菌蛋白。 3)鉴定编码癌症粘附和侵袭的基因。 4)构建基因突变体,克隆并表达这些基因。 5)与非癌症对照相比,检查细菌对癌细胞的捕获和入侵。预期结果:1)在SOS对抗癌药物的反应下,细菌-癌症相互作用期间将差异诱导细菌蛋白质。 2)敲除细菌的黏附侵袭基因会破坏细菌的黏附侵袭表型。 3)表达这些基因将指导细菌捕获和入侵癌细胞。假说的含义细菌可以进化靶向转移细胞的抗癌表型。如果这个假设是正确的,结果将有助于开发一种新型的细菌抗转移方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号